EmamiQ1 FY25

Emami Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹412.6P/E: 23.9Market Cap: ₹18.0K CrSector: Personal Products

Management growth scorecard

Revenue

Category 4

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4
  • Emami is optimistic about growth but cautious due to external factors like monsoon variability and economic conditions.
  • Volume growth expectation is around 5-6% with 1-2% value growth.
  • Kesh King aims for at least 5% growth after strategic revamp.
  • Male Grooming segment is expected to deliver higher growth compared to Kesh King.
  • The Man Company and Brillare target 20-25% growth rates.
  • Healthcare and summer-linked portfolios like Navratna and Dermicool showing strong double-digit growth.
  • Digital and new brand portfolios are in investment phases with improving margins expected.
  • Advertising spends remain robust with potential margin expansion despite higher A&P spends.
  • Overall revenue growth guidance is cautious, awaiting favorable monsoon and winter seasons.
  • Inorganic growth via strategic investments and acquisitions remains a key part of long-term strategy.

See what Emami management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The company discusses a strong balance sheet and mentions openness to inorganic growth opportunities but does not detail any immediate capital raising.
  • Strategic investments have been made in subsidiaries like The Man Company and Brillare, indicating use of existing resources rather than new fundraising.
  • The focus appears to be on internal cash generation and a robust balance sheet to support growth and acquisitions.
  • No explicit guidance or announcements on new equity or debt issuance were made during the call.

See what Emami management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Emami is open to inorganic growth as part of its long-term strategy.
  • The company has made strategic investments in The Man Company and Brillare, both of which have become subsidiaries.
  • Emami continues to look for more inorganic opportunities, supported by a strong balance sheet.
  • The Man Company and Brillare are expected to grow 20%-25% and contribute around 8% of revenues this year.
  • New digital-first products and D2C brands (like Zanducare) have been launched, with ongoing investments in these ventures.
  • Some digital and new brand portfolios are currently in the investment phase, with improving margins and break-even expected soon.
  • The company plans to support key launches through e-commerce and modern trade channels, gradually rolling out to other states.
  • No specific capex figure or timeline was disclosed during the call; decisions on retail market extensions will be taken in coming months.

Track Emami — get its next earnings analysis in your feed

How does Emami rank vs peers in Personal Products?

Pro feature
ThisEmami
Rev 4Mar 2

How does Emami rank in Personal Products?

Compare Emami against every Personal Products company (Q1 FY25) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

Others in Personal Products this season

  • Anondita Medicare (Q2 FY27)

    Revenue (Standalone)** for H1 FY27: ₹5,786.31 Lakhs, up 21.43% YoY from ₹4,765.06 Lakhs in H1 FY26 . Key investor presentation takeaways from Anondita Medicare

  • Gillette India (Q2 FY27)

    Revenue from operations for the quarter ended 30th September 2026: ₹84,610 lakh (Page 3) . Key results statement takeaways from Gillette India Ltd's Q2 FY27 ear

  • Cupid (Q2 FY27)

    Q2 FY27 revenue from operations: ₹187.86 Crores, up 122.5% YoY (Q2 FY26: ₹84.45 Crores) [Page 14, 16] . Key investor presentation takeaways from Cupid Ltd's Q2

  • Honasa Consumer (Q2 FY27)

    Younger brands, excluding The Derma Co., are growing healthily at 40%+ year-on-year, with the overall portfolio showing strong momentum across online and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →